US regulatory status: approved.
pharma · Activated Phosphoinositide 3-Kinase Delta Syndrome · primary immunodeficiency
Pharming Technologies
Pharming Technologies B.V.
Pharming Technologies drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Leiden, NL HQ
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Leiden, NL
- Employees
- 6
- Programs
- 8
- Drugs
- 11
- Patents
- 0
Pharming Technologies pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Pharming Technologies drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
caffeine
Nervous system (N06)US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Adenosine receptor antagonist
-
furosemide
Cardiovascular system (C03)US regulatory status: approved. Molecular target: Solute carrier family 12 member 1.
- Target
- Solute carrier family 12 member 1
- Mechanism
- Sodium-(potassium)-chloride cotransporter 2 inhibitor
-
Development asset linked to Pharming Technologies in public FDA and regional records.
-
Development asset linked to Pharming Technologies in public FDA and regional records. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform.
- Target
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
- Mechanism
- PI3-kinase p110-delta subunit inhibitor
-
Development asset linked to Pharming Technologies in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Pharming Technologies in public FDA and regional records.
-
Development asset linked to Pharming Technologies in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Pharming Technologies in public FDA and regional records.